Rho GTPase activating protein 25Genealiases: HEL-S-308 · KAIA0053
Q-omics provides the consensus-scored ARHGAP25 profile across patient tissues and cancer cell-line models. ARHGAP25 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ARHGAP25 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ARHGAP25 protein abundance shows 22,730 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where ARHGAP25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP25 survival associations across molecular data types. ARHGAP25 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP25 RNA expression–survival associations across cancer types. High ARHGAP25 expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, HNSC, LUAD and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ARHGAP25 RNA expression.
This table summarizes ARHGAP25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARHGAP25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP25 shows lower tumor expression in LUAD, COAD, UCEC and LUSC and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher ARHGAP25 RNA expression in tumor versus normal tissue (log2 FC = +1.866, t-test p < 0.001).
This table shows molecular features associated with ARHGAP25 in patient tissues and cancer cell lines. In patient samples, ARHGAP25 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
